2007
DOI: 10.1007/s11102-007-0020-3
|View full text |Cite
|
Sign up to set email alerts
|

TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature

Abstract: Thyrotropin (TSH)-secreting pituitary adenomas account for less than 1% of all pituitary tumors. In the last two decades, their clinical management has changed markedly due to technological advances that made earlier diagnosis possible and the introduction of somatostatin analog therapy. We retrieved the data of 11 patients in Israel diagnosed with TSH-secreting pituitary tumors since 1989. There were six men and five women of mean age 44.8 +/- 19.5 years (range 18-80 years). All had elevated thyroxine and tri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
11
0
2

Year Published

2009
2009
2020
2020

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 45 publications
(14 citation statements)
references
References 21 publications
1
11
0
2
Order By: Relevance
“…And this adenoma was not fibrous but soft enough to remove with suction and gentle curettage unlike a report by Sanno et al [11]. On the other hand, intrasphenoidal adenomectomy caused profuse epidural/ dural hemorrhaging, which is compatible with previous suggestions: The majority of TSHomas are macroadenomas and invasive [1,12]. Our speculation is that cellulose, microfibrillar collagen hemostat, and so on to control bleeding during adenomectomy.…”
Section: Discussionsupporting
confidence: 85%
“…And this adenoma was not fibrous but soft enough to remove with suction and gentle curettage unlike a report by Sanno et al [11]. On the other hand, intrasphenoidal adenomectomy caused profuse epidural/ dural hemorrhaging, which is compatible with previous suggestions: The majority of TSHomas are macroadenomas and invasive [1,12]. Our speculation is that cellulose, microfibrillar collagen hemostat, and so on to control bleeding during adenomectomy.…”
Section: Discussionsupporting
confidence: 85%
“…1,2,5,7 Their diagnosis and management are often difficult and challenging. [2][3][4][5][6]11,13 Our study demonstrates that multimodality treatment of TSH-omas results in long-term clinical remission in virtually all patients. Furthermore, the rates of apparent surgical cure are low, the tumours seem refractory to irradiation, and the majority of the patients are still in need of medical therapy during long-term follow-up.…”
Section: Discussionmentioning
confidence: 99%
“…Decrease in tumour mass was reported in approximately 40% of the cases. 2,5,7,10 Nevertheless, due to the low prevalence, there are relatively few studies that describe a series of patients with thyrotrophinomas, 3,4,6,7,[11][12][13][14] and the place of SSA treatment in the management of TSH-omas still remains to be fully established.…”
Section: Introductionmentioning
confidence: 99%
“…[7][8][9][10] If surgery is contraindicated or if it fails to cure, the European Thyroid Association guidelines strongly recommend treatment with somatostatin analogs (SSA), such as octreotide and lanreotide, which have proved to be highly effective in a series of studies. [9][10][11][12][13][14][15][16][17][18][19] However, there are cases where manifestation of adverse effects, resistance to or escape from the inhibitory effect of SSAs lead to failure of treatment. 15,18,19 In these cases stereotactic irradiation can be employed.…”
Section: Introductionmentioning
confidence: 99%